Weightloss drug

As the New Year begins, the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) is urging the public to avoid purchasing weight-loss medicines without a prescription from unauthorized sources like beauty salons, social media platforms, or unverified websites. Such practices...

On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio, Inc. In March, iBio collaborated with AstralBio to discover, engineer, and develop antibodies to...

On Friday, Novo Nordisk A/S (NYSE:NVO) stock plunged after the company released headline results from the REDEFINE 1 Phase 3 trial in the global REDEFINE program. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg...

On Thursday, Vivani Medical Inc. (NASDAQ:VANI) initiated screening and enrollment at two centers in Australia for the first-in-human clinical trial, LIBERATE-1. The trial investigates the safety, tolerability, and full pharmacokinetic profile of an exenatide implant. Vivani’s lead program,...

A recent cohort study conducted in Denmark and Norway reveals a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). Semaglutide is the key ingredient in Novo Nordisk A/S' (NYSE:NVO) Ozempic and Wegovy,...

GoodRx Holdings (NASDAQ:GDRX), a prescription savings platform in the U.S., has released its latest Weight Loss Medications Tracker, revealing a sharp increase in the use of popular weight loss drugs like Eli Lilly And Co’s (NYSE:LLY) Mounjaro and Zepbound, and Novo Nordisk A/S’ (NYSE:...

Danish pharmaceutical company Novo Nordisk A/S (NYSE:NVO) said it will officially launch its weight-loss drug Wegovy in China. China’s National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese. Wegovy is the world’s first weekly glucagon-...

Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related portfolio, has highlighted the ongoing difficulties Americans face in accessing branded GLP-1 medications. To address the issue, the company launched a GLP-1 Supply Tracker,...

At the ObesityWeek 2024, AstraZeneca Plc (NASDAQ:AZN) shared data abstracts highlighting early data from AZD5004/ECC5004. In November 2023, AstraZeneca announced an exclusive license agreement with Eccogene for potential obesity treatment, ECC5004, an investigational oral once-daily...

On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial. Last year, Novo Nordisk’s subcutaneous once-weekly (injectable) semaglutide 2.4 mg, available as Wegovy, showed a 20% reduction in MACE compared to placebo.  The SOUL...

A recent real-world data analysis was conducted to suggest a link between glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) prescriptions and reduced rates of opioid overdose and alcohol intoxication among patients with opioid use disorder (...

Last week, the FDA determined the shortage of Eli Lilly And Co's (NYSE:LLY) tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. The U.S. health regulator reminded compounders of the legal restrictions on making copies of FDA-approved drugs. The update...

NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to achieve significant clinical outcomes. Tirzepatide, branded as Mounjaro and produced by Eli Lilly And Co (NYSE:LLY), has shown remarkable results in clinical trials. It offers...

The demand for GLP-1 agonists, including Novo Nordisk A/S’s (NYSE:NVO) Ozempic and Wegovy (semaglutide), a class of drugs used to manage diabetes and obesity, continues to grow. Though initially developed for type 2 diabetes, GLP-1s have gained attention for their effectiveness in weight...

Pharmaceutical giant Eli Lilly and Co (NYSE:LLY) is reportedly exploring broader applications for its popular weight-loss drugs, Mounjaro and Zepbound. The company is considering clinical trials targeting individuals with a lower body mass index (BMI), expanding beyond the obese patient population...